Zogenix to Participate in Two Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zogenix (NASDAQ: ZGNX) announced management participation in two investor conferences: the Raymond James Human Health Innovation Conference on June 23, 2021, focusing on epilepsy treatment advancements, and the SVB Leerink CNS Forum on June 29, 2021, discussing underappreciated assets. Presenters include Michael Smith, CFO, and Stephen Farr, CEO. Zogenix is committed to therapies for rare diseases, with FDA-approved FINTEPLA for Dravet syndrome and ongoing development for other conditions like Lennox-Gastaut syndrome.
Details
News Market Reaction – ZGNX
The recorded move for ZGNX in the trading session of this news was +0.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming investor conferences: the Raymond James Human Health Innovation Conference and SVB Leerink CNS Forum.
| Raymond James Human Health Innovation Conference | |
| Panel: | Recent Advancements & Future Directions in the Treatment of Epilepsy |
| Date: | Wednesday, June 23, 2021 |
| Time: | 4:00 PM Eastern Time |
| Presenter: | Michael Smith, Executive Vice President and Chief Financial Officer |
| SVB Leerink CNS Forum | |
| Fireside Chat: | Reviewing Two Underappreciated Zogenix Assets |
| Date: | Tuesday, June 29, 2021 |
| Time: | 11:50 AM Eastern Time |
| Presenters: | Stephen J. Farr, Ph.D., President and Chief Executive Officer and Michael Smith, Executive Vice President and Chief Financial Officer |
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.